Exact Mass: 660.3873

Croton factor F1

C38H60O9 (660.4237)

D009676 - Noxae > D002273 - Carcinogens > D010703 - Phorbol Esters

Tsugaric acid A 21-glucosyl ester

C38H60O9 (660.4237)

Tsugaric acid A 21-glucosyl ester is found in mushrooms. Tsugaric acid A 21-glucosyl ester is a constituent of Ganoderma tsugae (red reishi). Constituent of Ganoderma tsugae (red reishi). Tsugaric acid A 21-glucosyl ester is found in mushrooms.

26-Deoxyactein

C37H56O10 (660.3873)

PA(10:0/PGE2)

C33H57O11P (660.3638)

PA(10:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGE2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGE2/10:0)

C33H57O11P (660.3638)

PA(PGE2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/10:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/PGD2)

C33H57O11P (660.3638)

PA(10:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/PGD2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGD2/10:0)

C33H57O11P (660.3638)

PA(PGD2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/10:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C33H57O11P (660.3638)

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0)

C33H57O11P (660.3638)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(14:0/18:1(12Z)-O(9S,10R))

C35H65O9P (660.4366)

PA(14:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/14:0)

C35H65O9P (660.4366)

PA(18:1(12Z)-O(9S,10R)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/14:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(14:0/18:1(9Z)-O(12,13))

C35H65O9P (660.4366)

PA(14:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/14:0)

C35H65O9P (660.4366)

PA(18:1(9Z)-O(12,13)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/14:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-14:0/18:1(12Z)-O(9S,10R))

C35H65O9P (660.4366)

PA(i-14:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/i-14:0)

C35H65O9P (660.4366)

PA(18:1(12Z)-O(9S,10R)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/i-14:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-14:0/18:1(9Z)-O(12,13))

C35H65O9P (660.4366)

PA(i-14:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/i-14:0)

C35H65O9P (660.4366)

PA(18:1(9Z)-O(12,13)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/i-14:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

26-Deoxyactein

C37H56O10 (660.3873)

26-Deoxyactein is a triterpenoid. It has a role as a metabolite. 26-Deoxyactein is a natural product found in Actaea elata, Actaea cimicifuga, and Actaea racemosa with data available. See also: Black Cohosh (part of). A natural product found in Actaea racemosa.

Gypsogenin-3-O-glucuronide

C37H56O10 (660.3873)

Gypsogenin-3-O-glucuronide is a ubiquitous saponin precursor in plants of the genus Gypsophila[1]. Gypsogenin-3-O-glucuronide is a ubiquitous saponin precursor in plants of the genus Gypsophila[1].

(-)-Umbellamine

C41H48N4O4 (660.3675)

27-Deoxyactein

C37H56O10 (660.3873)

Khekadaengoside C

C36H52O11 (660.3509)

Accedinine

C41H48N4O4 (660.3675)

Villalstonine

C41H48N4O4 (660.3675)

Cimiracemoside K

C37H56O10 (660.3873)

A natural product found in Actaea racemosa.

Wikstroelide J

C36H52O11 (660.3509)

Eupassofilin

C38H60O9 (660.4237)

Khekadaengoside I

C36H52O11 (660.3509)

(-)-Reveromycin B

C36H52O11 (660.3509)

Reveromycin A

C36H52O11 (660.3509)

Concanamycin G

C38H60O9 (660.4237)

25-O-acetyl-7,8-didehydrocimigenol 3-O-alpha-L-arabinopyranoside

C37H56O10 (660.3873)

C36H52O11

C36H52O11 (660.3509)

Antibiotic S 39163F1|S39163/F-I

C38H60O9 (660.4237)

CUMINDYSOSIDE A

C37H56O10 (660.3873)

rosmanoyl carnosate

C40H52O8 (660.3662)

C37H56O10

C37H56O10 (660.3873)

15-oxozoapatlin-13alpha-yl-10alpha,16alpha-dihydroxy-9alpha-methyl-20-nor-kauran-19-oic acid gamma-lactone-17-oate

C40H52O8 (660.3662)

gambogenin dimethyl acetal

C40H52O8 (660.3662)

(18S)-hydroxyneodihydroprotolichesterinic acid 18-O-alpha-L-rhamnopyranosyl-(1-2)-O-beta-D-glucopyranoside-(21,2-lactone)|gobienine B

C33H56O13 (660.3721)

C38H60O9

C38H60O9 (660.4237)

meliavolen

C41H56O7 (660.4026)

C41H56O7

C41H56O7 (660.4026)

3,11,22-Trioxo-16??-hydroxy-(20S,24)-epoxy-cucurbit-5,23-diene-2??-O-??-D-glucopyranoside

C36H52O11 (660.3509)

2-{[5,7-dihydroxy-2-methyl-2-(4-methyl-3-pentenyl)-8-butanoyl-6-chromenyl]methyl}-3,5-dihydroxy-4-methyl-4-(3,7-dimethyl-2,6-octadienyl)-6-acetyl-2,5-cyclohexadien-1-one|yungensin C

C40H52O8 (660.3662)

wattoside D

C33H56O13 (660.3721)

2-O-beta-D-glucopyranosyl cucurbitacin S

C36H52O11 (660.3509)

(25S)-5beta-furostan-1beta,2beta,3beta,4beta,5beta,22alpha,26-heptaol-26-O-beta-D-glucoside

C33H56O13 (660.3721)

aphanamene B

C40H52O8 (660.3662)

cercosporene F

C40H52O8 (660.3662)

11alpha,12alpha-epoxy-3beta-[(O-beta-D-glucuronopyranoside-6-O-methly ester)oxy]olean-28,13-olide|gardeniside A

C37H56O10 (660.3873)

Aphadilactone B

C40H52O8 (660.3662)

21,24,25-triacetyl-7-deacetyl-6-hydroxylbrujavanone E

C36H52O11 (660.3509)

Callistenone E

C40H52O8 (660.3662)

villalstonidine F

C41H48N4O4 (660.3675)

C39H52N2O7

C39H52N2O7 (660.3774)

saccharolidin A

C38H60O9 (660.4237)

4-apo-beta-caroten-4-oic acid beta-D-glucopyranoside|neurosporaxanthin beta-D-glucopyranoside

C41H56O7 (660.4026)

3-Epiwightiaol A tetraacetate

C38H60O9 (660.4237)

3beta-O-(4-deoxy-beta-D-hex-4-enopyranosyluronic acid), 2beta-hydroxy-olean-12-en-23,18-dioic acid

C36H52O11 (660.3509)

3-O-(3-Acetyl-beta-D-xylopyranoside)--16,23:16,24-Diepoxycycloart-7-ene-3,15,25-triol

C37H56O10 (660.3873)

Trp Leu Lys Ser Asn

C31H48N8O8 (660.3595)

Tyr Val Arg Pro Leu

C32H52N8O7 (660.3959)

23-epi-26-Deoxyactein

C37H56O10 (660.3873)

23-epi-26-deoxyactein is a triterpenoid. It has a role as a metabolite. 23-EPI-26-Deoxyactein is a natural product found in Actaea racemosa with data available. See also: Black Cohosh (part of). A natural product found in Actaea racemosa. 23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound[1][2][3].

25-O-acetyl-7,8-didehydro-cimigenol-3-O-b-Dxylopyaranoside

C37H56O10 (660.3873)

C37H56O10_(2S,4aR,5aR,7R,7aR,8R,12aS,12bS,14aR)-1,1,5,7a,8,12a-Hexamethyl-2-(D-xylopyranosyloxy)hexadecahydro-2H-spiro[cyclopropa[1,8a]naphtho[2,1:4,5]indeno[2,1-b]pyran-10,2-[3,6]dioxabicyclo[3.1.0]hexan]-7-yl acetate

C37H56O10 (660.3873)

Neurosporaxanthin β-D-glucopyranoside

C41H56O7 (660.4026)

Carbaprostacyclin-biotin

C36H60N4O5S (660.4284)

Tsugaric acid A 21-glucosyl ester

C38H60O9 (660.4237)

OKDdiA-PA

C33H57O11P (660.3638)

Neurosporaxanthin beta-D-glucopyranoside

C41H56O7 (660.4026)

D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

2-(1,1-Dimethylethyl)-6-methyl-4-[3-[[2,4,8,10-tetrakis(1,1-dimethyleth yl)dibenzo[d,f][1,3,2]dioxaphosphepin-6-yl]oxy]propyl] phenol

C42H61O4P (660.4307)

PA(10:0/PGE2)

C33H57O11P (660.3638)

PA(PGE2/10:0)

C33H57O11P (660.3638)

PA(10:0/PGD2)

C33H57O11P (660.3638)

PA(PGD2/10:0)

C33H57O11P (660.3638)

PA(14:0/18:1(12Z)-O(9S,10R))

C35H65O9P (660.4366)

PA(18:1(12Z)-O(9S,10R)/14:0)

C35H65O9P (660.4366)

PA(i-14:0/18:1(12Z)-O(9S,10R))

C35H65O9P (660.4366)

PA(18:1(12Z)-O(9S,10R)/i-14:0)

C35H65O9P (660.4366)

PA(i-14:0/18:1(9Z)-O(12,13))

C35H65O9P (660.4366)

PA(18:1(9Z)-O(12,13)/i-14:0)

C35H65O9P (660.4366)

[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropyl] tetradecanoate

C35H65O9P (660.4366)

[(2R)-1-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] tetradecanoate

C35H65O9P (660.4366)

PA(10:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C33H57O11P (660.3638)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/10:0)

C33H57O11P (660.3638)

Yungensin C

C40H52O8 (660.3662)

A natural product found in Elaphoglossum yungense.

lumutinine C

C41H48N4O4 (660.3675)

A natural product found in Alstonia macrophylla.

Allodesmosine

C30H56N6O10+6 (660.4058)

N-[(3S,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3R,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

methyl (1R,21R,23R,24S,27E,28S,29S)-27-ethylidene-8,21,40-trimethyl-20,22-dioxa-8,25,30,40-tetrazaundecacyclo[23.11.2.16,17.124,28.01,23.03,21.04,18.07,15.09,14.023,30.031,36]tetraconta-7(15),9,11,13,31,33,35-heptaene-29-carboxylate

C41H48N4O4 (660.3675)

N-[[(3S,9R,10R)-16-(benzenesulfonamido)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-4-(dimethylamino)-N-methylbutanamide

C34H52N4O7S (660.3557)

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3R,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9R,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

1-(1,3-benzodioxol-5-yl)-3-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(phenylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C37H48N4O7 (660.3523)

N-[(3R,9R,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9S,10R)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3S,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

N-[(3R,9S,10S)-9-[[benzenesulfonyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-(dimethylamino)butanamide

C34H52N4O7S (660.3557)

[(1R,3R,4R,6R,12S,13S,16R,18S,21R)-1,4,6,12,17,17-hexamethyl-18-[(3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3-yl] acetate

C37H56O10 (660.3873)

Mgdg O-26:7_3:0

C38H60O9 (660.4237)

PE-Cer 17:3;2O/18:5

C37H61N2O6P (660.4267)

PE-Cer 15:3;2O/20:5

C37H61N2O6P (660.4267)

PE-Cer 13:2;2O/22:6

C37H61N2O6P (660.4267)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C35H65O9P (660.4366)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C35H65O9P (660.4366)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] tridecanoate

C35H65O9P (660.4366)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] undecanoate

C35H65O9P (660.4366)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C35H65O9P (660.4366)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (Z)-tridec-9-enoate

C35H65O9P (660.4366)

PEtOH 32:8

C37H57O8P (660.3791)

[(4E,8E,12E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]tetradeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C37H61N2O6P (660.4267)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C34H61O10P (660.4002)

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C34H61O10P (660.4002)

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C34H61O10P (660.4002)

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C34H61O10P (660.4002)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C34H61O10P (660.4002)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C34H61O10P (660.4002)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C34H61O10P (660.4002)

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C37H57O8P (660.3791)

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C34H61O10P (660.4002)

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C37H57O8P (660.3791)

[1-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C37H56O10 (660.3873)

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C34H61O10P (660.4002)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C37H57O8P (660.3791)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C34H61O10P (660.4002)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate

C37H57O8P (660.3791)

[1-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C37H56O10 (660.3873)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H61O10P (660.4002)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

C37H57O8P (660.3791)

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C34H61O10P (660.4002)

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C34H61O10P (660.4002)

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C34H61O10P (660.4002)

MGDG O-28:8;O

C37H56O10 (660.3873)

MGDG O-29:7

C38H60O9 (660.4237)

MGMG 29:7

C38H60O9 (660.4237)

SQMG 24:4

C33H56O11S (660.3543)

DGGA 25:1;O

C34H60O12 (660.4085)

DGGA 27:7

C36H52O11 (660.3509)

MGGA 28:7

C37H56O10 (660.3873)

PA O-20:0/12:3;O2

C35H65O9P (660.4366)

PA O-31:4;O3

C34H61O10P (660.4002)

PA O-32:3;O2

C35H65O9P (660.4366)

PA P-20:0/11:3;O3

C34H61O10P (660.4002)

PA P-20:0/12:2;O2

C35H65O9P (660.4366)

PA 14:0/18:2;O

C35H65O9P (660.4366)

PA 14:1/18:1;O

C35H65O9P (660.4366)

PA 18:0/13:3;O2

C34H61O10P (660.4002)

PA 18:1/12:3;O3

C33H57O11P (660.3638)

PA 18:2/12:2;O3

C33H57O11P (660.3638)

PA 22:1/8:3;O3

C33H57O11P (660.3638)

PA 22:2/8:2;O3

C33H57O11P (660.3638)

PA 22:2/9:1;O2

C34H61O10P (660.4002)

PA 31:3;O2

C34H61O10P (660.4002)

PA 32:2;O

C35H65O9P (660.4366)

PG O-27:5;O2

C33H57O11P (660.3638)

PG O-28:4;O

C34H61O10P (660.4002)

PG P-16:0/12:3;O

C34H61O10P (660.4002)

PG P-18:0/9:4;O2

C33H57O11P (660.3638)

PG P-20:0/8:3;O

C34H61O10P (660.4002)

PG P-20:1/7:3;O2

C33H57O11P (660.3638)

PG 14:1/13:3;O

C33H57O11P (660.3638)

PG 18:3/9:1;O

C33H57O11P (660.3638)

PG 20:1/7:3;O

C33H57O11P (660.3638)

PG 27:4;O

C33H57O11P (660.3638)

PG 10:0_18:3

C34H61O10P (660.4002)

PG 28:3

C34H61O10P (660.4002)

PEth 30:2;O

C35H65O9P (660.4366)

PEth 32:8

C37H57O8P (660.3791)

PM 31:2;O

C35H65O9P (660.4366)

PM 32:9;O

C36H53O9P (660.3427)

PM 33:8

C37H57O8P (660.3791)

ST 27:0;O7;GlcA

C33H56O13 (660.3721)

ST 27:1;O8;Hex

C33H56O13 (660.3721)

ST 28:0;O7;Hex

C34H60O12 (660.4085)

Boc-Glu-Lys-Lys-AMC

C32H48N6O9 (660.3483)

Boc-Glu-Lys-Lys-AMC is a sensitive fluorogenic substrate for urokinase-activated plasmin[1].

(2s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2e,4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,10,15,19-pentamethyl-21-(2,6,6-trimethylcyclohex-1-en-1-yl)henicosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C41H56O7 (660.4026)

(2e)-4-{[(1s,2r,4s,7z,10r,11r)-4-(hydroxymethyl)-8-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.0²,⁴]tetradec-7-en-10-yl]oxy}-3-methyl-4-oxobut-2-en-1-yl (3s)-3-hydroxyoctadecanoate

C38H60O9 (660.4237)

6,7,34,35-tetrahydroxy-33-(hydroxymethyl)-5,12,29-trimethyl-2,4,9,14,30,32-hexaoxatetracyclo[29.4.0.0³,⁸.0¹¹,¹⁵]pentatriacontane-10,13-dione

C33H56O13 (660.3721)

(1s,2s,5s,8r,11r,12r)-2,12-dimethyl-6-methylidene-7,17-dioxo-16-oxapentacyclo[10.3.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-5-yl (1s,2s,5r,6r,8s,11r,12r)-6-hydroxy-2,12-dimethyl-17-oxo-16-oxapentacyclo[10.3.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-6-carboxylate

C40H52O8 (660.3662)

methyl 5,9-dimethyl-14-methylidene-15-{[3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H52O11 (660.3509)

8-(3,9-dihydroxy-4,8-dimethyl-5-oxodec-6-en-2-yl)-20-hydroxy-9-methoxy-1,3,13-trimethyl-16-pentyl-7,17,19-trioxabicyclo[13.4.1]icosa-2,4,10,12-tetraen-6-one

C38H60O9 (660.4237)

2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-9-[(3,4,5-trihydroxyoxan-2-yl)oxy]-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-16-yl acetate

C37H56O10 (660.3873)

(2s,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2e,4e,6e,8e,10e,12e,14e,16e,18e,20e)-2,6,10,15,19-pentamethyl-21-(2,6,6-trimethylcyclohex-1-en-1-yl)henicosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C41H56O7 (660.4026)

cimiracemoside j

C37H56O10 (660.3873)

12-o-palmitoyl-16-hydroxyphorbol

C38H60O9 (660.4237)

{"Ingredient_id": "HBIN000955","Ingredient_name": "12-o-palmitoyl-16-hydroxyphorbol","Alias": "NA","Ingredient_formula": "C38H60O9","Ingredient_Smile": "CCCCCCCCCCCCCCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)CO)OC(=O)C)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25380","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

16,23:16,24-diepoxycycloart-7-ene-3,15,25-triol; (3β,15α,23r,24r)-form,3-o-(3-acetyl-beta-d-xylopyranoside)

C37H56O10 (660.3873)

{"Ingredient_id": "HBIN001756","Ingredient_name": "16,23:16,24-diepoxycycloart-7-ene-3,15,25-triol; (3\u03b2,15\u03b1,23r,24r)-form,3-o-(3-acetyl-beta-d-xylopyranoside)","Alias": "NA","Ingredient_formula": "C37H56O10","Ingredient_Smile": "NA","Ingredient_weight": "660.83","OB_score": "NA","CAS_id": "150972-76-2","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9285","PubChem_id": "NA","DrugBank_id": "NA"}

23-epi-26-deoxyactein

C37H56O10 (660.3873)

{"Ingredient_id": "HBIN004083","Ingredient_name": "23-epi-26-deoxyactein","Alias": "NA","Ingredient_formula": "C37H56O10","Ingredient_Smile": "CC1CC2(C3C(O3)(CO2)C)OC4C1C5(C(CC67CC68CCC(C(C8CCC7C5(C4)C)(C)C)OC9C(C(C(CO9)O)O)O)OC(=O)C)C","Ingredient_weight": "660.8 g/mol","OB_score": "8.3194382","CAS_id": "NA","SymMap_id": "SMIT12810","TCMID_id": "NA","TCMSP_id": "MOL011990","TCM_ID_id": "NA","PubChem_id": "101182169","DrugBank_id": "NA"}

3,11,22-trioxo-16α-hydroxy-(20s,24)-epoxy-cucurbit-5,23-diene-2β-o-β-d-glucopyrano-side

C36H52O11 (660.3509)

{"Ingredient_id": "HBIN006895","Ingredient_name": "3,11,22-trioxo-16\u03b1-hydroxy-(20s,24)-epoxy-cucurbit-5,23-diene-2\u03b2-o-\u03b2-d-glucopyrano-side","Alias": "NA","Ingredient_formula": "C36H52O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21969","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

3-o-α-(2''-o-acetyl)-d-xylopyranosyl-3β-hy-droxyolean-12-ene-28,29-dioicacid

C37H56O10 (660.3873)

{"Ingredient_id": "HBIN009052","Ingredient_name": "3-o-\u03b1-(2''-o-acetyl)-d-xylopyranosyl-3\u03b2-hy-droxyolean-12-ene-28,29-dioicacid","Alias": "3-o-alpha-(2''-o-acetyl)-d-xylopyranosyl-3beta-hydroxyolean-12-ene-28,29-dioic acid","Ingredient_formula": "C37H56O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "533;30356","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

acteol; 26-deoxy,12-ac,3-o-beta-d-xylopyranoside

C37H56O10 (660.3873)

{"Ingredient_id": "HBIN014628","Ingredient_name": "acteol; 26-deoxy,12-ac,3-o-beta-d-xylopyranoside","Alias": "NA","Ingredient_formula": "C37H56O10","Ingredient_Smile": "NA","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7172","PubChem_id": "NA","DrugBank_id": "NA"}

cimiracemoside n

C37H56O10 (660.3873)

(1r,2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-16-yl acetate

C37H56O10 (660.3873)

(2e)-4-{[(1s,2s,4s,7e,10r,11r)-4-(hydroxymethyl)-8-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.0²,⁴]tetradec-7-en-10-yl]oxy}-3-methyl-4-oxobut-2-en-1-yl (3r)-3-hydroxyoctadecanoate

C38H60O9 (660.4237)

(2z,4z,10z,12z)-8-[(6e)-3,9-dihydroxy-4,8-dimethyl-5-oxodec-6-en-2-yl]-20-hydroxy-9-methoxy-1,3,13-trimethyl-16-pentyl-7,17,19-trioxabicyclo[13.4.1]icosa-2,4,10,12-tetraen-6-one

C38H60O9 (660.4237)

10-[9-butyl-8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)

4-{[4-(hydroxymethyl)-8-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.0²,⁴]tetradec-7-en-10-yl]oxy}-3-methyl-4-oxobut-2-en-1-yl 3-hydroxyoctadecanoate

C38H60O9 (660.4237)

5-(2-{3,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-2,6-dioxo-1h,4h,7h,8h,9h,10h-cyclohexa[f]azulen-5-yl}ethyl)-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H52O8 (660.3662)

(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1r,3r,6s,8r,12r,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl]butyl acetate

C37H56O10 (660.3873)

methyl (1r,3s,4s,6s,17s,18s,21r,23r,24s,27e,28s,29r)-27-ethylidene-8,21,40-trimethyl-20,22-dioxa-8,25,30,40-tetraazaundecacyclo[23.11.2.1⁶,¹⁷.1²⁴,²⁸.0¹,²³.0³,²¹.0⁴,¹⁸.0⁷,¹⁵.0⁹,¹⁴.0²³,³⁰.0³¹,³⁶]tetraconta-7(15),9,11,13,31,33,35-heptaene-29-carboxylate

C41H48N4O4 (660.3675)

(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1r,3r,6s,8r,12r,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl]butyl acetate

C37H56O10 (660.3873)

(1r,7s,10s,18s,21s,24s)-7,24-dihydroxy-15,29-diisopropyl-9,9,22,22-tetramethyl-2,17,32,33-tetraoxanonacyclo[16.8.4.2⁵,¹².2¹⁹,²⁶.0¹,¹⁸.0³,¹⁶.0⁴,¹³.0⁵,¹⁰.0²¹,²⁶]tetratriaconta-3,13,15,29-tetraene-27,28-dione

C40H52O8 (660.3662)

[(2r,3s,4s,5r,6r)-6-{[(1s,2r,3r,5r,7r,10s,11r,14r,15s)-7-(acetyloxy)-2,6,6,10-tetramethyl-15-[(2s)-3-methylidene-4-oxobutan-2-yl]pentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C37H56O10 (660.3873)

(1s,1'r,2s,3'r,4'r,5s,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C37H56O10 (660.3873)

(4r)-2-acetyl-6-{[(2r)-8-butanoyl-5,7-dihydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-6-yl]methyl}-4-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one

C40H52O8 (660.3662)

[(1s,2s,4s,5r,8r,9r,10s,13s,14r,17s,18r)-2-hydroxy-4,5,9,13,20,20-hexamethyl-10-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-9-yl]methyl acetate

C38H60O9 (660.4237)

(1s,1'r,2s,3'r,4'r,5s,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C37H56O10 (660.3873)

(1s,1'r,2r,3'r,4'r,5s,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C37H56O10 (660.3873)

(1s,2s,13s,15r)-15-[(2z)-4,4-dimethoxy-3-methylbut-2-en-1-yl]-7-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C40H52O8 (660.3662)

1-(3,3-dimethyloxiran-2-yl)-3-{13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl}butyl acetate

C37H56O10 (660.3873)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C38H60O9 (660.4237)

(1r,2r,3as,3br,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)

2-hydroxy-1-(2-hydroxy-6-methyl-3-oxohept-6-en-2-yl)-3a,6,6,9b,11a-pentamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)

(3e,5z,7r,8r,9s,10s,11r,13z,15z,17s,18r)-18-[(2s,3r,4s,6e,8s,9r,10e)-3,9-dihydroxy-4,8-dimethyl-5-oxododeca-6,10-dien-2-yl]-8,10-dihydroxy-3,17-dimethoxy-5,7,9,11,13-pentamethyl-1-oxacyclooctadeca-3,5,13,15-tetraen-2-one

C38H60O9 (660.4237)

(7r,8ar,10ar)-5-{2-[(1r,7s,8ar,10ar)-3,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-2,6-dioxo-1h,4h,7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]ethyl}-2,7-dihydroxy-1-isopropyl-8a,10a-dimethyl-7h,8h,9h,10h-cyclohexa[f]azulene-3,6-dione

C40H52O8 (660.3662)

(1s,2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-9-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-16-yl acetate

C37H56O10 (660.3873)

2-{2-hydroxy-3,8,8,17,19-pentamethyl-9-[(3,4,5-trihydroxyoxan-2-yl)oxy]-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracos-4-en-22-yl}propan-2-yl acetate

C37H56O10 (660.3873)

(1r,2r,3as,3bs,9ar,9br,11ar)-2-hydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxohept-6-en-2-yl]-3a,6,6,9b,11a-pentamethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthrene-7,10-dione

C36H52O11 (660.3509)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(1r,3ar,5ar,7s,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C38H60O9 (660.4237)

13-(acetyloxy)-1,6-dihydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O9 (660.4237)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r)-2-[(3ar,5ar,7r)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C38H60O9 (660.4237)

2-[(2r,5s)-5-[(1s,3ar,3br,5as,7r,9r,9ar,9bs,11r,11ar)-7,9,11-tris(acetyloxy)-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5-methyloxolan-2-yl]propan-2-yl acetate

C38H60O9 (660.4237)

4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C37H56O10 (660.3873)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2,6,10,15,19-pentamethyl-21-(2,6,6-trimethylcyclohex-1-en-1-yl)henicosa-2,4,6,8,10,12,14,16,18,20-decaenoate

C41H56O7 (660.4026)

(6-{[7-(acetyloxy)-2,6,6,10-tetramethyl-15-(3-methylidene-4-oxobutan-2-yl)pentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methyl acetate

C37H56O10 (660.3873)

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-3b,6,6,9a,11a-pentamethyl-1-[(3s)-6-(propan-2-ylidene)oxan-3-yl]-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H56O7 (660.4026)

(1s,2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

C36H52O11 (660.3509)

(1r,8s,9s,10s)-3,4-dihydroxy-5-isopropyl-11,11-dimethyl-15-oxo-16-oxatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6-trien-8-yl (4ar,10as)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylate

C40H52O8 (660.3662)

(2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-22-(prop-1-en-2-yl)-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-16-yl acetate

C37H56O10 (660.3873)

reveromycin b

C36H52O11 (660.3509)

methyl (1r,12s,14s,15e,18s)-15-ethylidene-12-[(1r,12r,13s,14s,15e)-15-ethylidene-1-hydroxy-13-(hydroxymethyl)-3-methyl-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-7-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C41H48N4O4 (660.3675)

(1s,2s,6r,10s,11r,12r,13s,14r,15r)-13-(acetyloxy)-1,6-dihydroxy-8,12-bis(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-14-yl hexadecanoate

C38H60O9 (660.4237)

methyl (1r,4s,5r,9s,10r,13r,15r)-5,9-dimethyl-14-methylidene-15-{[(2r,3r,4r,5r,6r)-3,4,5-tris(acetyloxy)-6-[(prop-1-en-2-yloxy)methyl]oxan-2-yl]oxy}tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H52O11 (660.3509)

(1r,3s,5s,6r,7r,8r,11r,12r,15s,29s,31r,33r,34s,35s)-6,7,34,35-tetrahydroxy-33-(hydroxymethyl)-5,12,29-trimethyl-2,4,9,14,30,32-hexaoxatetracyclo[29.4.0.0³,⁸.0¹¹,¹⁵]pentatriacontane-10,13-dione

C33H56O13 (660.3721)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C38H60O9 (660.4237)

(2e,4r,5r,6e,8e)-10-[(2s,3r,6r,8r,9s)-9-butyl-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)

(1s,2s,4r,6s,7s,8r,9s,10r,13s,14s)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)

3,4-dihydroxy-5-isopropyl-11,11-dimethyl-15-oxo-16-oxatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6-trien-8-yl 5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylate

C40H52O8 (660.3662)

2-[(1s,2s,3r,7s,9s,12r,14r,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracos-4-en-22-yl]propan-2-yl acetate

C37H56O10 (660.3873)

(2r,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6-chlorotridecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

C36H62Cl2O6 (660.3923)

2-[(1s,2s,3r,7s,9s,12r,14r,17r,18r,19r,21r,22s)-2-hydroxy-3,8,8,17,19-pentamethyl-9-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracos-4-en-22-yl]propan-2-yl acetate

C37H56O10 (660.3873)

(1s,7s,10s,18r,21s,24s)-7,24-dihydroxy-15,29-diisopropyl-9,9,22,22-tetramethyl-2,17,32,33-tetraoxanonacyclo[16.8.4.2⁵,¹².2¹⁹,²⁶.0¹,¹⁸.0³,¹⁶.0⁴,¹³.0⁵,¹⁰.0²¹,²⁶]tetratriaconta-3,13,15,29-tetraene-27,28-dione

C40H52O8 (660.3662)

4,9-bis(acetyloxy)-3b,6,6,9a,11a-pentamethyl-1-[6-(propan-2-ylidene)oxan-3-yl]-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H56O7 (660.4026)

n-(1-acetyl-2-oxopyrrolidin-3-yl)-3-hydroxy-4-{[hydroxy(2-{3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl}-1,2-diazinan-3-yl)methylidene]amino}-2-methyl-5-phenylpentanimidic acid

C32H48N6O9 (660.3483)

2,12-dimethyl-6-methylidene-7,17-dioxo-16-oxapentacyclo[10.3.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-5-yl 6-hydroxy-2,12-dimethyl-17-oxo-16-oxapentacyclo[10.3.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecane-6-carboxylate

C40H52O8 (660.3662)

(1r,1'r,2s,3'r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate

C37H56O10 (660.3873)

2-acetyl-6-{[8-butanoyl-5,7-dihydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)chromen-6-yl]methyl}-4-(3,7-dimethylocta-2,6-dien-1-yl)-3,5-dihydroxy-4-methylcyclohexa-2,5-dien-1-one

C40H52O8 (660.3662)

(2s,3s,4s)-n-[(3s)-1-acetyl-2-oxopyrrolidin-3-yl]-3-hydroxy-4-({hydroxy[(3s)-2-[(2r,3r)-3-hydroxy-2-[(1-hydroxy-2-methoxyethylidene)amino]-4-methylpentanoyl]-1,2-diazinan-3-yl]methylidene}amino)-2-methyl-5-phenylpentanimidic acid

C32H48N6O9 (660.3483)

(2s,4r,5s,6s,10s,11r,12r,13r,14s,15r)-13-(acetyloxy)-5,6,11,14-tetrahydroxy-4-(hydroxymethyl)-8,12-dimethyl-7-oxo-14-(prop-1-en-2-yl)-3-oxatetracyclo[9.4.0.0²,⁴.0⁶,¹⁰]pentadec-8-en-15-yl (2e,4e)-tetradeca-2,4-dienoate

C36H52O11 (660.3509)

(2e,4s,5s,6e,8e)-10-[(2r,7r,8s)-2-butyl-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-8-methyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid

C36H52O11 (660.3509)

(1s,2s,4r,6s,7r,8r,9r,10r,13r,14r)-7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)

7,8-dihydroxy-2,8,10,13,18,18-hexamethyl-6-(2-methylprop-1-en-1-yl)-16-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁴,¹⁹]henicosa-15,19-diene-12,17-dione

C36H52O11 (660.3509)

15-(4,4-dimethoxy-3-methylbut-2-en-1-yl)-7-(3,7-dimethylocta-2,6-dien-1-yl)-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-en-1-yl)-3,16-dioxapentacyclo[11.4.1.0²,¹¹.0²,¹⁵.0⁴,⁹]octadeca-4,6,8,11-tetraene-10,14-dione

C40H52O8 (660.3662)

(4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-9-formyl-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6s)-3,4,5-trihydroxy-6-(methoxycarbonyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C37H56O10 (660.3873)

(3e,5z,7r,8r,9s,10s,11r,13z,15z,17s)-18-[(2s,3r,4s,6e,10e)-3,9-dihydroxy-4,8-dimethyl-5-oxododeca-6,10-dien-2-yl]-8,10-dihydroxy-3,17-dimethoxy-5,7,9,11,13-pentamethyl-1-oxacyclooctadeca-3,5,13,15-tetraen-2-one

C38H60O9 (660.4237)